World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Research Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 4
Page: 601-603

ROLE OF QUALITY BY DESIGN (QBD) IN ENHANCING THE ROBUSTNESS OF SOLID ORAL DOSAGE FORMS

Dr. Deepak Shrivastava*

Shri Bherulal Pharmacy Institute, Indore, India.

Article Received: 01 July 2025 | | ***Article Revised: 22 July 2025*** | | ***Article Accepted: 15 August 2025***

***Corresponding Author: Dr. Deepak Shrivastava**
Shri Bherulal Pharmacy Institute, Indore, India.
DOI: https://doi.org/10.5281/zenodo.17010741

How to cite this Article: Dr. Deepak Shrivastava (2025) ROLE OF QUALITY BY DESIGN (QBD) IN ENHANCING THE ROBUSTNESS OF SOLID ORAL DOSAGE FORMS. World Journal of Pharmaceutical Science and Research, 4(4), 601-603. https://doi.org/10.5281/zenodo.17010741

Copyright © 2025 Dr. Deepak Shrivastava | World Journal of Pharmaceutical Science and Research.
This work is licensed under creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0)

ABSTRACT

Quality by Design (QbD) has revolutionized pharmaceutical product development by enabling a systematic approach to design and control processes that enhance product robustness. This review highlights the role of QbD principles, such as Critical Quality Attributes (CQAs), Critical Process Parameters (CPPs), and Design of Experiments (DoE), in improving the development and manufacturing of solid oral dosage forms. Incorporating QbD reduces batch failures, ensures consistent drug quality, and supports regulatory compliance. The implementation of Process Analytical Technology (PAT) and continuous lifecycle monitoring further contributes to the robustness of oral formulations. This study synthesizes current literature and case studies demonstrating how QbD fosters scalable, robust, and high-quality solid dosage forms.

KEYWORDS: Quality by Design, QbD, Robustness, Solid Oral Dosage Forms, Design Space, Critical Quality Attributes, Process Analytical Technology.

1. INTRODUCTION

In recent years, pharmaceutical development has shifted from traditional trial-and-error approaches to a science- and risk-based Quality by Design (QbD) methodology. QbD, as defined by the International Council for Harmonisation (ICH) guidelines Q8, Q9, and Q10, emphasizes designing quality into the product from the beginning by understanding the relationship between material attributes, process parameters, and final product quality. The robustness of solid oral dosage forms—tablets and capsules—is critical for ensuring therapeutic efficacy, patient safety, and regulatory approval. This review focuses on how QbD principles contribute to enhancing the robustness of these dosage forms by enabling systematic development and process control.

2. MATERIALS AND METHODS

This study is based on a comprehensive literature review of peer-reviewed journals, regulatory guidelines, and case studies focusing on the application of QbD in solid oral dosage form development. Databases searched include PubMed, ScienceDirect, and Google Scholar using keywords such as "Quality by Design," "solid oral dosage form," "robustness," "Design of Experiments," and "Process Analytical Technology."

3. RESULTS AND DISCUSSION

3.1 Core Components of QbD Enhancing Robustness

Component	Description	Role in Robustness
Quality Target Product Profile (QTPP)	Desired product attributes (e.g., dissolution rate, stability)	Defines design goals and quality criteria
Critical Quality Attributes (CQAs)	Physical, chemical, biological properties affecting quality	Focus areas for control and optimization
Critical Material Attributes (CMAs)	Characteristics of raw materials impacting CQAs	Ensures raw material consistency
Critical Process Parameters (CPPs)	Process variables that influence CQAs	Controlled to maintain product consistency
Design of Experiments (DoE)	Statistical method to study effects of variables	Optimizes formulation and process parameters
Design Space	Multidimensional range of CPPs and CMAs yielding quality	Regulatory flexibility within established space
Process Analytical Technology (PAT)	Real-time monitoring tools	Enables timely control and reduces batch failures

3.2 Quality Target Product Profile (QTPP) and Critical Quality Attributes (CQAs)

The QTPP sets the foundation for formulation by listing attributes such as dosage form, route of administration, release profile, and stability. CQAs are derived from QTPP to identify specific attributes that must be controlled. For example, hardness, friability, dissolution rate, and content uniformity are CQAs for tablets. Managing these attributes ensures the product performs consistently in vivo and meets regulatory standards.

3.3 Design of Experiments (DoE) and Design Space

DoE enables systematic experimentation to understand how formulation and process parameters affect CQAs. By analyzing interactions and main effects, a robust design space can be established where the product consistently meets specifications despite variability.



Figure 1: Shows a schematic of how DoE and Design Space help maintain robustness.

3.4 Process Analytical Technology (PAT) and Lifecycle Management

PAT tools, such as Near-Infrared Spectroscopy (NIR) and Raman spectroscopy, provide real-time monitoring of manufacturing processes. This enables immediate adjustments to maintain parameters within the design space, reducing

variability and improving batch-to-batch consistency. Continuous monitoring during lifecycle management supports sustained product quality.

3.5 CASE STUDY: Application of QbD in Tablet Formulation

A recent study optimized a fast-dissolving tablet of Flurbiprofen using QbD principles. DoE identified critical factors such as binder concentration and compression force affecting dissolution and hardness. Implementation of PAT ensured real-time control, reducing batch failures and achieving consistent drug release.

4. CONCLUSION

Quality by Design provides a robust framework for developing and manufacturing solid oral dosage forms with enhanced consistency and regulatory compliance. By integrating QbD principles—QTPP, CQAs, DoE, Design Space, and PAT—pharmaceutical scientists can design formulations that withstand variability in materials and processes, ensuring product quality throughout the lifecycle.

ACKNOWLEDGMENTS

The authors acknowledge the support of Shri Bherulal Pharmacy Institute and colleagues who contributed insights for this review.

REFERENCES

1. ICH Q8(R2) Pharmaceutical Development, International Council for Harmonisation, 2009.
2. QbD in pharmaceutical industry: Concepts and applications, AAPS PharmSciTech, 2018; 19(6): 2485-2497.
3. Patil, S. et al., Implementation of QbD for fast dissolving tablets, Int J Pharm Sci Res, 2021; 12(3): 1456-1464.
4. FDA Guidance for Industry, PAT – A Framework for Innovative Pharmaceutical Development, 2004.
5. Rathore, A.S., Quality by Design for Biopharmaceuticals, 2015.